Agouron Pharmaceuticals

Feb 05, 01
12:25 ET	HIV Resistance Survey Shows Majority of Physicians Choose Single Protease Inhibitor as First-Line Combination Therapy
Sep 18, 00
08:06 ET	No Difference in Adherence Indicated in Survey of Patients on ANTI-HIV Combination Therapies Containing Once or Twice Daily Agents
08:01 ET	Agouron Announces a Capravirine Clinical Trial For People Who Have Failed Previous Anti-HIV Therapy
Sep 14, 00
08:03 ET	Landmark Study on Lipodystrophy Demonstrates Evolving Perceptions By Physicians Who Treat People Living With HIV
Sep 08, 00
08:00 ET	RESCRIPTOR(R)-Containing Combination Therapy May Be Effective For People Failing Previous Anti-HIV Therapies
Jul 13, 00
08:03 ET	First Once-Daily VIRACEPT(R) Data Presented
08:03 ET	Survey of Patient Adherence Indicates No Difference Between Anti-HIV Combination Therapies Given Once or Twice Daily
08:03 ET	VIRACEPT(R) Taken Twice Daily (BID) Shown to Improve Adherence and Durable Anti-HIV Effects
Jul 11, 00
08:07 ET	For People Living With HIV, VIRACEPT(R) Combination Therapy Was Shown to Suppress Virus for Three Years
08:07 ET	RESCRIPTOR(R) Has Shown to Enhance HIV Protease Inhibitor Therapy
Jun 09, 00
07:00 ET	The Immune Response Corporation and Agouron Pharmaceuticals, Inc. Announce ACTG Study Update
Mar 17, 00
08:00 ET	Agouron Solves Structure of Key Target for Oncology: Checkpoint Kinase I
Mar 06, 00
08:00 ET	FDA Approves Film-Coated Formulation of VIRACEPT(R) Tablets
Feb 10, 00
10:15 ET	Agouron Completes Management Changes
Feb 02, 00
08:00 ET	Agouron Reports Results of VIRACEPT Combination Therapy in Pregnant Women and Newborns
08:00 ET	Triple Class Anti-HIV Therapy Provides Greater, More Durable Reduction Of HIV in Patients Who Experience Viral Rebound
Jan 30, 00
08:00 ET	Agouron's Capravirine Demonstrates Anti-HIV Activity in Clinical Trials
08:00 ET	HIV Protease Inhibitor Therapy Does Not Show Increased Risk Of Myocardial Infarction
Dec 13, 99
08:01 ET	Agouron's AG7088 Reduces Cold Symptoms in Phase II Trial
08:01 ET	Oracle Promotes Two Key Sales Executives
Nov 29, 99
07:59 ET	FDA Approves Twice Daily Dosing (BID) of VIRACEPT(R) - Agouron's HIV Protease Inhibitor
Nov 22, 99
08:00 ET	Agouron Announces Pilot Phase II Clinical Trial of Its Matrix Metalloprotease Inhibitor Prinomastat in Glioblastoma Multiforme
Nov 04, 99
08:01 ET	Agouron Initiates Large Clinical Trial of AG7088 For Treatment of the Common Cold
Oct 25, 99
08:07 ET	Agouron Acquires Rescriptor From Pharmacia & Upjohn; Non-Nucleoside Reverse Transcriptase Inhibitor Adds to Agouron's HIV Portfolio
Sep 27, 99
08:06 ET	Agouron and Immune Response Initiate Pivotal Trial of REMUNE, An Immune-Based Therapy for the Treatment of HIV Infection
Aug 19, 99
08:00 ET	Agouron Announces Confirmatory Trial of Oral Anti-Angiogenesis Drug Prinomastat for Treatment of Lung Cancer
May 17, 99
16:37 ET	Warner-Lambert and Agouron Pharmaceuticals, Inc. Close Merger Valued At $2.1 Billion
May 13, 99
18:45 ET	Agouron Reports Third Quarter 1999 Net Income
Mar 04, 99
09:00 ET	Agouron Solves Structure of Key Target for Drugs to Block Angiogenesis: Human VEGF Receptor 2 Kinase
Feb 03, 99
16:01 ET	Agouron Reports Consolidated Second Quarter 1999 Net Income
08:04 ET	VIRACEPT Therapy Produces Anti-HIV Effects in Women at Twelve Months
Feb 02, 99
08:03 ET	Agouron Pharmaceuticals, Inc. Prescribing Information for VIRACEPT
08:01 ET	Results Presented for Patients Switching from VIRACEPT to Other Protease Inhibitor Therapies
Feb 01, 99
08:04 ET	Agouron Reports Positive Resistance Results from Testing of Two Novel Anti-HIV Compounds
Jan 26, 99
16:06 ET	Warner-Lambert to Acquire Agouron for $2.1 Billion in Stock; Two Industry Leaders to Build Complementary Capabilities in Drug Discovery
Dec 16, 98
14:30 ET	Agouron Announces Approval of Divisional Stock Proposal
Dec 15, 98
09:01 ET	Agouron Initiates Human Clinical Trials of Drug For Treatment of the Common Cold
Oct 20, 98
16:00 ET	Agouron Reports First Quarter 1999 Net Income
Sep 26, 98
08:03 ET	Agouron Reports Results from Preclinical Testing of Compound For Treatment Of Common Cold Virus
08:00 ET	Agouron Reports Results from Preclinical Testing of Compound For Treatment Of Common Cold Virus
Sep 25, 98
13:22 ET	Twice Daily Dosing of Viracept Demonstrates Activity at 48 Weeks
Sep 15, 98
08:02 ET	Agouron Initiates Phase II Study of Oral Anti-Angiogenesis Drug AG3340 for Treatment of Age-Related Macular Degeneration
Aug 25, 98
13:30 ET	Agouron Pharmaceuticals, Inc. Prescribing Information for VIRACEPT
Aug 13, 98
07:01 ET	Agouron Files Registration Statement for Oncology Divisional Stock
Aug 12, 98
08:01 ET	Agouron Pharmaceuticals, Inc. Prescribing Information for VIRACEPT
08:00 ET	Agouron's Viracept Receives Marketing Approval in Canada
Jul 21, 98
16:00 ET	Agouron Reports 1998 Net Income; Announces Intention to Create Separate Oncology Division
Jul 02, 98
08:00 ET	Encouraging Preliminary Clinical Results Reported for Immune-Based Therapy REMUNE
Jun 30, 98
08:02 ET	Agouron Acquires New HIV Protease Inhibitor From Japan Energy Corporation
Jun 29, 98
08:05 ET	Agouron Acquires New Anti-HIV Drug from Shionogi
Jun 18, 98
12:38 ET	Alanex and Zeneca Form Strategic Collaboration to Discover Novel Agrochemicals
Jun 17, 98
08:03 ET	Phase I Data Presented on Agouron's Oral Anti-Angiogenesis Drug AG3340 in Patients With Advanced Cancer
Jun 11, 98
16:00 ET	Agouron and The Immune Response Corporation to Collaborate on Commercialization of REMUNE(TM)
May 05, 98
00:00 ET	Agouron Initiates Pivotal Trials of Oral Anti-Angiogenesis Drug AG3340 for Treatment of Lung Cancer and Prostate Cancer
Apr 14, 98
21:21 ET	Agouron Reports Third Quarter 1998 Net Income
Mar 06, 98
09:01 ET	Agouron Pharmaceuticals, Inc. Prescribing Information for VIRACEPT
09:00 ET	Agouron's VIRACEPT(R) Receives Approval in Japan
Feb 04, 98
08:01 ET	Clinical Study Indicates Patients Who Fail VIRACEPT(R) Therapy Are Not Excluded From Other Treatment Options
Feb 03, 98
09:03 ET	Agouron Summarizes VIRACEPT(R) Combination Studies
08:31 ET	VIRACEPT(R) Produces Durable Anti-HIV Effects For Two Years
08:04 ET	Twice Daily Dosing -- Another VIRACEPT(R) Treatment Option Evaluated For People Living With HIV/AIDS
08:03 ET	Agouron Pharmaceuticals, Inc. Prescribing Information for VIRACEPT
00:02 ET	Twice Daily Dosing -- Another VIRACEPT(R) Treatment Option Evaluated For People Living With HIV/AIDS
Jan 22, 98
10:30 ET	Agouron's Viracept Receives European Approval
Jan 12, 98
16:00 ET	Agouron Reports Second Quarter 1998 Net Income
Dec 03, 97
15:10 ET	Agouron Comments On Recent Decline In Stock Price
Dec 02, 97
08:02 ET	Agouron and Roche to End Cancer Collaboration; Agouron to Discontinue Development of AG337
Oct 07, 97
16:00 ET	Agouron Reports First Quarter 1998 Net Income
Oct 02, 97
08:30 ET	Agouron Reports Anticancer Collaboration With U.K. Organizations; Agouron to Immediately Optimize Lead Compounds
Jul 31, 97
16:00 ET	Agouron Pharmaceuticals Reports Fourth Quarter and Fiscal 1997 Financial Results; Announces 2 For 1 Stock Split
Jul 15, 97
09:06 ET	Agouron and JT Grant Roche Marketing Rights in Asia
Jun 30, 97
08:59 ET	Agouron Completes Management Changes
Jun 19, 97
08:03 ET	Agouron Initiates U.S. Clinical Trial of Anti-Cancer MMP Inhibitor AG3340
May 23, 97
16:19 ET	Agouron Completes Merger With Alanex Corporation
May 06, 97
09:05 ET	Agouron Expands Availability of VIRACEPT(TM) in Canada
Apr 29, 97
09:00 ET	Agouron Acquires Alanex Corporation
Apr 21, 97
08:04 ET	Agouron and Nastech to Join Forces in the Battle Against the Common Cold
Apr 14, 97
16:15 ET	Agouron Pharmaceuticals Reports Third Quarter 1997 Financial Results
08:09 ET	Agouron Reports Recent Results From Testing of Two Anticancer Drugs
Apr 11, 97
08:13 ET	Viracept Combination Therapy Drops HIV Below Quantifiable Levels in Both Blood and Lymph Tissue
Apr 07, 97
10:50 ET	Agouron Reports Anti-HIV Effects of VIRACEPT After Ten Months of Combination Therapy
10:48 ET	/C O R R E C T I O N -- Agouron/
08:06 ET	Agouron Reports Anti-HIV Effects of VIRACEPT After Ten Months of Combination Therapy
Mar 14, 97
12:58 ET	FDA Clears Agouron to Market VIRACEPT - A New HIV Protease Inhibitor for Adults and Children
Feb 19, 97
08:05 ET	Agouron Files European New Drug Application For Anti-HIV Drug VIRACEPT(R)
Jan 27, 97
08:01 ET	Agouron Pharmaceuticals Reports Second Quarter 1997 Financial Results
Jan 23, 97
08:05 ET	Agouron Reports Positive Results From Pivotal Clinical Trials of Viracept
Jan 20, 97
08:04 ET	Agouron's Anti-HIV Drug VIRACEPT(R) to be Marketed in Europe by Roche
Jan 08, 97
12:11 ET	Agouron to Enlarge VIRACEPT(R) Expanded Access Program For Adults
Jan 07, 97
08:04 ET	Agouron's Anti-HIV Drug VIRACEPT(R) to be Available to Children Through Expanded Access Program
Jan 06, 97
08:02 ET	Agouron Initiates VIRACEPT(R) Clinical Trial with the Community Programs for Clinical Research on AIDS (CPCRA)
Dec 23, 96
09:00 ET	Agouron Files New Drug Application for Anti-HIV Drug Viracept(R)
Nov 14, 96
11:01 ET	Vice President Gore's Hammer Award Presented To Los Angeles District FDA/Industry Regulatory Partnership
Nov 08, 96
08:00 ET	Agouron Adopts Shareholder Rights Plan
Oct 25, 96
08:00 ET	Agouron Pharmaceuticals Reports First Quarter 1997 Financial Results
Oct 24, 96
08:05 ET	Agouron To Submit NDA For Anti-HIV Drug VIRACEPT(TM)
03:00 ET	Agouron To Submit NDA For Anti-HIV Drug VIRACEPT(TM)
Oct 18, 96
08:01 ET	Agouron Scientists Solve Structure of Fourth Viral Target: Hepatitis C Protease
Sep 26, 96
08:02 ET	Agouron and Roche Initiate Clinical Trials of Anti-Cancer MMP Inhibitor AG3340
Sep 16, 96
08:02 ET	Agouron Announces Expanded Access Program For HIV Protease Inhibitor VIRACEPT(TM)
Sep 06, 96
08:00 ET	Agouron Scientists Solve Structure of CMV Protease
Aug 21, 96
08:02 ET	Agouron Pharmaceuticals Receives Clearance To Commence Clinical Trials Of New Cancer Drug
Aug 09, 96
08:00 ET	Agouron Pharmaceuticals Reports Fiscal 1996 Financial Results
Jul 25, 96
19:19 ET	AGOURON PHARMACEUTICALS ANNOUNCES COMPLETION OF PUBLIC OFFERING